University Lab Partners announced NovoThelium as the winner of the 2nd annual Golden Ticket Pitch Competition for aesthetic startups, sponsored by Allergan Aesthetics, an AbbVie company.
This year, five finalists were selected to present their innovative aesthetic technologies to an expert panel of judges, including Charlie Hee, Ph.D., Vice President, Devices, Aesthetics R&D at Allergan Aesthetics; Sherly Soleiman, M.D., Founder, Owner and Lead Injector at Cosmetic Injectable Center; and Michael Hill, Managing Director, Capital Markets at Octane.
Lauren Cornell, Ph.D., Co-Founder and CEO of Novothelium shared, "Winning the Golden Ticket from University Lab Partners and Allergan Aesthetics will provide NovoThelium with vital resources and mentorship, enabling us to enhance women's healthcare and pioneer innovations in nipple reconstruction post-mastectomy."
The Golden Ticket competition accelerates the research and development of startup aesthetics enterprises by offering the winner one year of free lab space at ULP, complete with state-of-the-art research equipment, professional support staff, conference rooms, and a vibrant, collaborative community. In addition, the winner gains access to invaluable industry mentorship, including from leaders at Allergan Aesthetics. "Allergan Aesthetics is honored and inspired to support Novothelium as part of our efforts to accelerate the growth and development of entrepreneurs and researchers in aesthetic medicine," says Darin Messina, Ph.D., Senior Vice President, Aesthetics R&D, AbbVie. "The Golden Ticket competition exemplifies our continued investment in early science and regenerative technologies and defining what's next for the aesthetics industry."
To learn more about The Golden Ticket, please visit www.universitylabpartners.org/our-events/golden-ticket-applications-open.